Nuformix has today filed another significant provisional patent application covering numerous novel solid forms of NX007, a leading cardiovascular drug.
With current annual sales growing to over £240m in 2009, NX007 is currently in late stage clinical trials for numerous new indications. The novel solid forms of NX007, re-engineered by Nuformix, offer greatly increased bioavailability for this very poorly water soluble drug.
The existing year-on-year sales growth of NX007 and high likelihood of approval for important new indications combine to make this filing a critical step forward for Nuformix in delivering against it’s strategy. As with NX006, the NX007 patent application was conceived together with Jeffrey A. Lindeman at the firm J. A. Lindeman LLC.